Wall Street’s concerns about GLP-1s’ impact on medical device makers was back in full swing after glucose monitoring device seller Dexcom (DXCM) slashed its full-year guidance after an earnings miss last week.
However, Dexcom’s troubles appear unrelated to the weight loss and diabetes drug…
[ad_2]
Source link
